許朝偉
, M.D.
單位: 林口長庚紀念醫院 / 長庚大學
現職: 胃腸肝膽科系 肝臟科主治醫師 / 醫學系 內科助理教授
聯絡地址: 桃園市龜山區復興街5 號
電話 / 傳真: 03-3281200 ext.8107 / Fax: 03-3272236
E-mail:
hsu2406@adm.cgmh.org.tw
研究領域:- 癌症
- 一般醫學
- 醫學實驗技術
- 藥物學
- 肝炎病毒及肝癌
工作經歷:成功大學附設醫院實習醫師, 林口長庚醫學中心住院醫師, 總醫師及主治醫師;
長庚大學醫學院助理教授
學歷:台北醫學大學藥學系; 國立成功大學醫學院學士後醫學系
代表論文:1. Hsu CW, Cheng JC, Yeh CT*. Quantitative assessment of serum NV-F virus DNA concentrations in samples from patients coinfected with hepatitis B or C virus. J Clin Microbiol 2006;44:3130-3133.
2. Hsu CW, Yeh CT*, Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamividine-treated patients experiencing seroclearance. Gastroenterology, 2007;132:543-550.
3. Lai CL*, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Fielman B, R.N., and Brown NA. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. N Engl J Med 2007;357:2576-88.
4. Hsu CW, Yeh CT*. Emergence of hepatitis B virus S gene mutants in patients experiencing HBsAg seroconversion after peginterferom therapy. Hepatology 2011;54(1):101-8.
5. Hsu CW*, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24. BMC Gastroenterol. 2012 Dec 13;12:178
所有論文著作一覽表
目前進行中的研究計畫1. 2012/1～Present > An open-label, randomized, active control study to evaluate the antiviral activity, safety and pharmacokinetics of P1101 + Ribavirin in treatment-naïve subjects with HCV genotype 1 infection. (PI, PharmaEssentia)
2. 2013/9～Present > An open-label, randomized, active control study to evaluate the antiviral activity, safety and pharmacokinetics of P1101 + Ribavirin in treatment-naïve subjects with HCV genotype 2 infection. (PI, PharmaEssentia)
3. 2013/10～Present > A multicenter open-label study to evaluate the safety and efficacy of PEG-IntronTM versus PEGASYSTM in subjects with HBeAg positive chronic hepatitis B and HBeAg negative chronic hepatitis B. (PI, MERCK)
4. 2013/11～Present > Phase IV; Different extend treatment duration (6 months vs 12 months after chemotherapy) to prevent HBV relapse with Tenofovir for prophylaxis in patients with malignant tumor combined with HBV carrier receiving chemotherapy. (PI, Investigator initiate study, Gilead)
5. 2011/5/1～2014/10/31> Dynamic Changes of Serum Hepatitis B Virus DNA and Surface Antigen Concentrations as Predictors for Subsequent e Antigen Seroconversion during Antiviral Therapy
殊榮:獲選肝病研究學術基金會的優秀論文獎 (2000-8); 優良病歷主治醫師獎, 優良教學主治醫師獎
學會與認證:- The Society of Internal Medicine, ROC
- The Gastroenterological Society of Taiwan
- The Digestive Endoscopy Society of Taiwan
- The Society of Ultrasound in Medicine, ROC
- The Formosan Medical Association, ROC
- European Association for the Study of the Liver (EASL)
- Taiwan Association for the Study of the Liver (TASL)
- Asian Pacific Association for the Study of the liver (APASL)